Over the past decade, “incremental innovation” (pharmaceutical innovations that improve on existing drug therapies) has accounted for 70% of the new drugs approved in the US and a substantial portion of the industry’s revenues. However, concerns that reformulated drugs are being used to delay or preclude generic competition have given rise to a number of high-profile antitrust suits, including cases concerning the drugs BuSpar, Nexium/Prilosec, and DDAVP, among others. Click here to download a PDF of this article:
2023 Annual Review of Antitrust Law Developments
CRA’s Yajing Jiang contributed to Chapter 1 “Restraints of Trade” of the 2023 Annual Review of Antitrust Law Developments recently published by the ABA...